StrataNGS with StrataEXP for CGP
Comprehensive treatment insights for more patients using less tissue.
The Strata Oncology tumor profiling platform combines DNA and RNA sequencing to deliver comprehensive cancer insights to help providers manage patients with advanced cancer. Our ability to provide deep cancer insights from minute tumor tissue samples ensures that more of your patients have the opportunity to benefit from precision medicine.
StrataNGS is a comprehensive genomic profiling (CGP) test that features the lowest tumor tissue requirements in the industry (>2mm2 surface area). The 429-gene assay is performed on co-isolated RNA and DNA. Single-/multi-nucleotide variants (SNVs), short insertions and deletions (indels), copy number alterations (CNAs; amplifications and deep deletions), microsatellite instability (MSI) status, gene fusions, and tumor mutation burden (TMB) are assessed simultaneously.
StrataEXP is a laboratory-developed multi-gene expression test. The 46 gene panel used for the assay was developed from data generated in conjunction with the StrataNGS test. StrataEXP uses RNA-sequencing to generate quantitative expression results from 10 expression biomarkers, which are targeted by multiple approved and investigational therapies, including antibodies, antibody drug conjugates, radiopharmaceuticals and immunotherapies. We currently provide StrataEXP results as supplemental information in order to offer physicians broader molecular insights into each patient’s cancer. If a physician orders the StrataNGS® test for comprehensive molecular profiling, no additional tissue is required to perform StrataEXP....
More Info Less Info